Vinod Pullarkat Selected Research

ruxolitinib

1/2022	Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study.
1/2021	Refractory primary autoimmune myelofibrosis treated with ruxolitinib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vinod Pullarkat Research Topics

Disease

43	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2024 - 12/2012
35	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/2023 - 05/2008
14	Neoplasms (Cancer) 03/2024 - 05/2007
11	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2023 - 04/2005
11	Leukemia 01/2022 - 08/2011
9	Philadelphia Chromosome 01/2023 - 05/2008
9	Primary Myelofibrosis (Myelosclerosis) 01/2022 - 01/2003
7	Thrombocytopenia (Thrombopenia) 02/2024 - 10/2012
6	Neutropenia 02/2024 - 04/2003
6	Residual Neoplasm 02/2022 - 11/2007
6	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2021 - 02/2008
5	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2023 - 12/2009
5	Chromosome Aberrations (Chromosome Abnormalities) 01/2021 - 05/2007
4	Hematologic Neoplasms (Hematological Malignancy) 04/2024 - 10/2014
4	Breast Neoplasms (Breast Cancer) 03/2024 - 05/2007
4	Infections 01/2020 - 06/2008
4	Iron Overload 01/2020 - 12/2009
3	Anemia 03/2024 - 01/2010
3	Febrile Neutropenia 12/2023 - 01/2020
3	Systemic Mastocytosis 02/2023 - 10/2014
3	Hemorrhage 01/2021 - 03/2009
3	Hyperbilirubinemia 12/2020 - 03/2014
3	Venous Thromboembolism 01/2019 - 09/2002
2	Venous Thrombosis (Deep-Vein Thrombosis) 01/2024 - 07/2014
2	Leukopenia 12/2023 - 04/2003
2	Pneumonia (Pneumonitis) 12/2023 - 12/2022
2	Pathologic Complete Response 01/2022 - 01/2020
2	Nausea 01/2020 - 06/2008
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2019 - 07/2017
2	Cytopenia 01/2017 - 01/2003
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2016 - 08/2011
2	Sickle Cell Anemia (Hemoglobin S Disease) 06/2015 - 01/2014
2	Hyperplasia 11/2014 - 01/2014
2	Fibrosis (Cirrhosis) 11/2014 - 01/2003
2	Bronchiolitis Obliterans Syndrome 01/2014 - 04/2005
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 03/2011 - 10/2005
1	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 03/2024
1	Hemolytic Anemia 03/2024
1	Fatigue 03/2024
1	Constipation 12/2023

Drug/Important Bio-Agent (IBA)

28	venetoclaxIBA 05/2024 - 01/2018
8	Azacitidine (5 Azacytidine)FDA Link 02/2024 - 01/2019
8	Sirolimus (Rapamycin)FDA Link 01/2023 - 02/2010
8	Tacrolimus (Prograf)FDA LinkGeneric 01/2022 - 04/2005
7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 10/2005
6	blinatumomabIBA 01/2023 - 09/2017
6	Inosine Triphosphate (ITP)IBA 01/2021 - 02/2008
5	Decitabine FDA Link 01/2023 - 01/2019
5	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2023 - 01/2014
5	Tyrosine Kinase InhibitorsIBA 09/2019 - 07/2015
5	IronIBA 06/2016 - 12/2009
4	fludarabineIBA 11/2023 - 01/2014
4	Core Binding Factors (Core-Binding Factor)IBA 01/2021 - 12/2012
4	Etoposide (VP 16)FDA LinkGeneric 01/2020 - 10/2005
4	pegaspargase (Oncaspar)FDA Link 01/2019 - 03/2014
3	Chimeric Antigen ReceptorsIBA 09/2023 - 12/2021
3	Proteins (Proteins, Gene)FDA Link 10/2020 - 03/2011
3	Busulfan (Busulfex)FDA Link 01/2020 - 02/2010
3	EnzymesIBA 01/2019 - 01/2013
3	Asparaginase (Elspar)FDA Link 01/2018 - 03/2014
3	AutoantibodiesIBA 01/2017 - 01/2003
3	Ferritins (Ferritin)IBA 03/2015 - 01/2010
2	fms-Like Tyrosine Kinase 3IBA 01/2024 - 10/2020
2	Ado-Trastuzumab EmtansineIBA 09/2023 - 01/2023
2	trastuzumab deruxtecanIBA 09/2023 - 01/2023
2	Immunoconjugates (Immunoconjugate)IBA 09/2023 - 01/2023
2	Inotuzumab OzogamicinIBA 01/2023 - 12/2022
2	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2023 - 01/2021
2	Thrombopoietin ReceptorsIBA 01/2023 - 01/2021
2	NucleosidesIBA 01/2022 - 09/2019
2	Melphalan (Alkeran)FDA LinkGeneric 01/2022 - 01/2020
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 06/2008
2	ruxolitinibIBA 01/2022 - 01/2021
2	Dasatinib (BMS 354825)FDA Link 11/2019 - 10/2016
2	AntioxidantsIBA 01/2019 - 01/2014
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 01/2014
2	romiplostim FDA Link 02/2015 - 02/2008
2	Reticulin (Reticular Fiber)IBA 11/2014 - 01/2003
2	Deferasirox FDA Link 08/2014 - 01/2013
2	Chelating AgentsIBA 08/2014 - 01/2013
2	Thrombopoietin (c-mpl Ligand)IBA 10/2012 - 01/2011
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 11/2006 - 04/2005
1	midostaurinIBA 04/2024
1	BilirubinIBA 03/2024
1	Complement Inactivating AgentsIBA 03/2024
1	Hemoglobins (Hemoglobin)IBA 03/2024
1	gilteritinibIBA 01/2024

Therapy/Procedure

39	Therapeutics 05/2024 - 05/2007
27	Cell Transplantation 01/2023 - 11/2006
15	Drug Therapy (Chemotherapy) 04/2024 - 05/2007
8	Hematopoietic Stem Cell Transplantation 01/2021 - 12/2009
6	Transplantation 01/2023 - 06/2008
5	Salvage Therapy 01/2021 - 04/2005
3	Homologous Transplantation 01/2022 - 12/2017
3	Stem Cell Transplantation 12/2017 - 10/2005
2	Induction Chemotherapy 05/2024 - 07/2015
2	Immunotherapy 04/2024 - 12/2021
2	Treatment Delay 01/2023 - 03/2014
2	Lymphatic Irradiation 01/2022 - 04/2017
1	Central Venous Catheters 01/2024